Nuclear Medicine/Radiopharmaceuticals [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha radiation therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & Stable Isotopes...

NEW YORK, Aug. 7, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Nuclear Medicine/Radiopharmaceuticals [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha radiation therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & Stable Isotopes (Deuterium, C-13) Market - Global Trends & Forecast to 2017
http://www.reportlinker.com/p01157679/Nuclear-Medicine/Radiopharmaceuticals-[SPECT/PET-Radioisotopes-Technetium-F-18]-[Beta/Alpha-radiation-therapy-I131-Y-90]-[Applications-Cancer/Oncology-Cardiac]--Stable-Isotopes-Deuterium-C-13-Market---Global-Trends--Forecast-to-2017.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Imaging

The global radiopharmaceuticals market was valued at $3.8 billion in 2012 and is poised to reach $5.5 billion by 2017 at a CAGR of 7.8%.

A study conducted by Organization for Economic Co-operation and Development (OECD) estimates that Tc-99m diagnostic procedures are expected to increase by 15% to 20% in mature markets such as Europe, North America, Japan, the Republic of Korea, and Oceania between 2010 and 2030. Radiopharmaceuticals in neurological applications such as Alzheimer's disease, Parkinson's disease, and dementia are also being preferred by practitioners besides conventional treatment. Further, upcoming radioisotopes such as Ra-223 (Alpharadin) and Ga-68 possess huge potential for clinical applications. The scheduled shutdown of the NRU reactor in 2016 and OSIRIS in France in 2018 is, however, a major threat for manufacturers.

The therapy market is predominantly driven by its oncologic applications. Since conventional treatment procedures of cancer, surgery and chemotherapy have significant side effects, radioisotopes are being preferred by medical practitioners due to minimum or no side effects. The radiopharmaceutical therapy market is expected to grow significantly with the launch of the much-desired Alpharadin (Ra-223) in the near future. This isotope has tremendous potential to take up market share of beta emitters and brachytherapy.

North America is the dominant market for diagnostic radioisotopes with 49% share. The U.S. is the largest consumer market for radiopharmaceuticals in North America, while Canada is one of the largest producers of Tc-99m. Major players in the radiopharmaceuticals market are Cardinal Health, Inc. (U.S.), Covidien, Plc (Ireland), GE Healthcare (U.K.), IBA Group (Belgium), Lantheus Medical Imaging, Inc. (U.S.), Nordion, Inc. (Canada), and Siemens Healthcare (PETNET) (Germany).

The stable isotopes market was led by two players - Cambridge Isotope Laboratories (CIL) (U.S.) and Isotec (Sigma Aldrich) (U.S.) - in 2012; they jointly contributed more than 90% to the global revenue.

Scope of the Report

The radioisotope and stable isotope markets have been segmented according to the type of isotope, and applications. Both of these markets are broken down into segments and sub-segments, providing exhaustive value analysis for the years 2010, 2011, 2012, and forecast to 2017. Each market is comprehensively analyzed at a granular level by geography (North America, Europe, Asia, and Rest of the World) to provide in-depth information on the global scenario.

Global Radiopharmaceuticals Market

Diagnostic
SPECT
Tc-99m
Tl-201
Ga-67
I-123
Others
PET
F-18
Rb-82
Others

Therapy
Beta emitters
I-131
Sm-153
Re-186
Y-90
Lu-177
Others

Alpha emitters
Brachytherapy
Cs-131
I-125
Pd-103
Ir-192
Others

Global Enriched Stable Isotopes Market
Deuterium
Oxygen-18
Carbon-13
Nitrogen-15
Others

Radiopharmaceutical and Stable Isotope Markets, By Geography
North America
Europe, including Russia
Asia
RoW (Africa, LATAM, Middle-East, Pacific countries)

TABLE OF CONTENTS

1 INTRODUCTION 28

1.1 KEY TAKE-AWAYS 28
1.2 REPORT DESCRIPTION 28
1.3 MARKETS COVERED 30
1.4 STAKEHOLDERS 31
1.5 RESEARCH METHODOLOGY 32
1.5.1 MARKET SIZE 32
1.5.2 MARKET SHARE 33
1.5.3 KEY DATA POINTS FROM SECONDARY SOURCES 33
1.5.4 KEY DATA POINTS FROM PRIMARY SOURCES 33
1.5.5 ASSUMPTIONS 34

2 EXECUTIVE SUMMARY 35

3 MARKET OVERVIEW 40

3.1 DEFINITION OF RADIOPHARMACEUTICALS 41
3.2 EVOLUTION 41
3.3 MARKET SEGMENTATION 43
3.3.1 RADIOPHARMACEUTICALS 43
3.3.2 STABLE ISOTOPES 44
3.4 MARKET DYNAMICS 45
3.4.1 DRIVERS 46
3.4.1.1 Increasing incidence of cancer and cardiac ailments boosts the demand for radiopharmaceuticals 46
3.4.1.2 Increasing use of SPECT and PET scans results in rise of radiopharmaceutical usage 46
3.4.1.3 Rising awareness of radiopharmaceuticals to spur growth 47
3.4.1.4 Ready availability of radiopharmaceuticals from cyclotrons to goad the growth 47
3.4.2 RESTRAINTS 48
3.4.2.1 Shorter half-life of radiopharmaceuticals restricts its usage 48
3.4.2.2 High capital to limit the buying of scanners 48
3.4.2.3 Stringent regulatory guidelines and GMP to negatively impact growth 48
3.4.2.4 Competition from conventional diagnostic procedures 49
3.4.3 OPPORTUNITIES 50
3.4.3.1 Potential radioisotopes in the pipeline 50
3.4.3.2 High demand in emerging countries 50
3.4.3.3 Alpha radio immunotherapy-based targeted cancer treatment 51
3.4.3.4 Alternative diagnostic radiopharmaceutical solutions 51
3.4.3.5 Cyclotron based production 52
3.4.3.6 Neurological applications 52
3.4.4 THREAT 52
3.4.4.1 Shutdown of nuclear reactors to impact production of radioisotopes 52
3.5 WINNING IMPERATIVES 53
3.5.1 INVESTMENTS ON NEW RADIOISOTOPES AND NOVEL APPLICATIONS 53
3.5.2 SHIFT TOWARDS LEU-BASED MO-99 PRODUCTION 54
3.6 BURNING ISSUES 54
3.6.1 HIGH COST OF PET CAMERAS 54
3.6.2 SHORTAGE IN SUPPLY OF TECHNETIUM-99M 54
3.7 MARKET SHARE ANALYSIS 55
3.7.1 RADIOPHARMACEUTICALS MARKET 55
3.7.2 ENRICHED STABLE ISOTOPES MARKET 58
3.8 VALUE CHAIN ANALYSIS 59
3.8.1 SPECT (MOLYBDENUM-99/TECHNETIUM-99M) 59
3.8.1.1 Pricing structure in different phases of the value chain 60
3.8.1.2 Cost modeling – LEU based Tc-99m production 63
3.8.2 PET (FLUORINE-18) 66
3.8.3 STABLE ISOTOPE (DEUTERIUM) 67
3.9 PIPELINE ANALYSIS 69
3.9.1 DIAGNOSTIC RADIOISOTOPES 70
3.9.2 THERAPEUTIC RADIOISOTOPES 74
3.10 DEMAND & SUPPLY ANALYSIS 77
3.10.1 DEMAND FOR MO-99/TC-99M 78
3.10.1.1 Availability of SPECT cameras to stabilize demand 79
3.10.1.2 Stringent regulatory and reimbursement procedures for alternative isotopes prevents shift from Tc-99 80
3.10.1.3 Emerging markets will enhance usage of Tc-99m 80
3.10.1.4 Potential growth of Tc-99m based diagnostic imaging 80
3.10.1.5 Shift from SPECT to PET 81
3.10.2 CURRENT STATUS OF MO-99 SUPPLY 81
3.11 STRATEGIC BENCHMARKING 86
3.11.1 PROCESSORS' SHIFT FROM HEU TO LEU BASED MO-99 86
3.11.1.1 Contract extension by Nordion with AECL & supply agreement with RIAR 87
3.11.1.2 Agreement of Covidien & IAE POLATOM with Maria reactor 88
3.11.1.3 Agreement of NTP Radioisotopes with Lantheus Medical Imaging 88
3.11.2 SUSTAINABLE SUPPLY CHAIN BY GENERATORS 88
3.11.2.1 Contract extension of Lantheus Medical Imaging Inc., with NTP Radioisotopes (Pty) Ltd. 90
3.11.2.2 Extension of contract & acquisition by IBA Group 90
3.11.2.3 Acquisition of CNS Therapeutics, Inc., by Covidien, Plc. 90
3.11.2.4 Collaboration of NTP Radioisotopes Pty Ltd. with ANSTO 90
3.11.2.5 Expansion and agreement of FujiFilm Holdings Corporation 91
3.12 REGULATORY AFFAIRS 91
3.12.1 GUIDELINES IN THE U.S. 91
3.12.2 GUIDELINES IN EUROPE 92
3.12.3 REIMBURSEMENT 92
3.12.4 SAFETY OF PERSONNEL 93
3.12.5 WASTE DISPOSAL 93
3.12.6 EQUIPMENT & FACILITY 94
3.12.7 TRANSPORTATION GUIDELINES 95

4 GLOBAL RADIOPHARMACEUTICALS MARKET, BY VALUE 96

4.1 INTRODUCTION 97
4.2 DIAGNOSTIC MARKET 97
4.2.1 OPPORTUNITY MATRIX 98
4.2.2 SPECT RADIOPHARMACEUTICALS 99
4.2.2.1 Technetium-99m (Tc-99m) 102
4.2.2.1.1 Tc-99m to decide growth trend of SPECT radioisotopes 104
4.2.2.1.2 Factors affecting Technetium-99m market 105
4.2.2.1.2.1 Technetium can combine with 31 different carrier molecules 105
4.2.2.1.2.2 Lack of availability of technetium 105
4.2.2.2 Thallium-201 (Tl-201) 106
4.2.2.2.1 Tl-201 is a potential substitute for Tc-99m 106
4.2.2.3 Gallium-67 (Ga-67) 108
4.2.2.3.1 Fluorine-18 might seize Ga-67 market share in the near future 108
4.2.2.4 Iodine (I-123) 109
4.2.2.5 Others 111
4.2.3 PET RADIOPHARMACEUTICALS 112
4.2.3.1 Fluorine-18 116
4.2.3.1.1 FDG 116
4.2.3.1.2 Florbetapir 116
4.2.3.1.3 Factors affecting Fluorine-18 market 118
4.2.3.1.3.1 Increasing availability of PET machines 118
4.2.3.1.3.2 Rise in PET procedures increases demand for FDG 118
4.2.3.1.3.3 High generation costs of FDG 118
4.2.3.1.3.4 Need for speedy & efficient transportation 118
4.2.3.2 Rubidium-82 (Rb-82) 119
4.2.3.2.1 Bracco re-launched CardioGen-82 in February 2012 119
4.2.3.3 Others 120
4.2.3.3.1 Ga-68 deemed as a potential PET radioisotope 120
4.3 THERAPEUTIC MARKET 122
4.3.1 OPPORTUNITY MATRIX 122
4.3.2 BETA EMITTERS 123
4.3.2.1 Iodine-131 (I-131) 126
4.3.2.2 Yttrium-90 (Y-90) 127
4.3.2.2.1 Y-90 market influenced by popularity of Nordion's TheraSphere 128
4.3.2.3 Samarium-153 (Sm-153) 129
4.3.2.4 Rhenium-186 (Re-186) 130
4.3.2.5 Lutetium-177 (Lu-177) 131
4.3.2.5.1 Lu-177 is a potential treatment option for neuroendocrine cancer 131
4.3.2.6 Others 132
4.3.2.6.1 Re-188 and P-33 are notable promising isotope 133
4.3.3 ALPHA EMITTERS 134
4.3.3.1 Radium-223 (Ra-223) & Alpharadin 134
4.3.3.1.1 Successful completion of Phase III trials in men with bone metastases from CRPC 136
4.3.3.1.2 First in-class alpha pharmaceutical 136
4.3.3.1.3 Alpharadin is advantageous over Taxotere, beta-therapy and brachytherapy 136
4.3.3.1.4 Success of Alpharadin 137
4.3.3.1.5 Porter's five forces analysis 137
4.3.3.1.6 Alpharadin market potential post launch 138
4.3.3.1.7 SWOT Analysis 139
4.3.3.2 Actinium-225 (Ac-225) 140
4.3.3.3 Lead-212 (Pb-212)/Bismuth-212 (Bi-212) 141
4.3.3.4 Astatine-211 (At-211) 141
4.3.3.5 Radium-224 (Ra-224) 141
4.3.3.6 Thorium-227 (Th-227) 141
4.3.4 BRACHYTHERAPY 142
4.3.4.1 U.S. to show slow growth due to reimbursement issues 144
4.3.4.2 Cesium-131 146
4.3.4.3 Iodine-125 147
4.3.4.4 Palladium-103 147
4.3.4.5 Iridium-192 148
4.3.4.6 Others 149

5 GLOBAL RADIOPHARMACEUTICALS MARKET, BY PROCEDURAL VOLUME 151

5.1 INTRODUCTION 152
5.1.1 HOSPITAL BASED & LOCAL REACTORS GENERATED ISOTOPES TO BOOST THE PROCEDURAL MARKET 152
5.2 DIAGNOSTIC MARKET 155
5.2.1 SPECT RADIOPHARMACEUTICALS 156
5.2.2 PET RADIOPHARMACEUTICALS 158
5.3 THERAPEUTIC MARKET 160
5.3.1 BETA EMITTERS 161
5.3.2 BRACHYTHERAPY 163

6 RADIOPHARMACEUTICALS MARKET, BY APPLICATION/ INDICATION 165

6.1 INTRODUCTION 166
6.2 DIAGNOSTIC MARKET 166
6.2.1 SPECT 167
6.2.1.1 Cardiology 168
6.2.1.2 Lymphoma 170
6.2.1.3 Thyroid 171
6.2.1.4 Neurology 172
6.2.1.4.1 Alzheimer's, dementia, and Parkinson's disease drives growth of the neurology SPECT market 172
6.2.1.5 Others 173
6.2.2 PET APPLICATION 174
6.2.2.1 Oncology 175
6.2.2.1.1 FDG F-18 has become a gold standard for oncology diagnosis using PET scan 175
6.2.2.2 Cardiology 176
6.2.2.3 Neurology 178
6.2.2.3.1 Florbetapir F-18 & Fluorodopa (F-18 dopa) are potential substitutes of FDG F-18 178
6.2.2.4 Others 179
6.3 THERAPEUTIC APPLICATION 181
6.3.1 THYROID 182
6.3.2 BONE METASTASIS 183
6.3.3 LYMPHOMA 185
6.3.3.1 Novel clinical studies goading lymphoma therapy market 185
6.3.4 ENDOCRINE TUMORS 186
6.3.5 OTHERS 187

7 ENRICHED STABLE ISOTOPES MARKET 189

7.1 INTRODUCTION 190
7.2 MARKET OVERVIEW 191
7.2.1 ASIA ACCOUNTS FOR LARGEST MARKET SHARE 191
7.3 MARKET DYNAMICS 192
7.3.1 DRIVERS 192
7.3.1.1 Stable isotopes are natural in origin & hence safe 192
7.3.1.2 Proteomics & system biology, major factors to boost the growth of stables 192
7.3.1.3 Medical applications propel stable isotopes market growth 192
7.3.2 RESTRAINTS 193
7.3.2.1 Harmful effects of stable isotopes affect market growth 193
7.3.2.2 High cost of stables isotope 193
7.4 ENRICHED STABLES MARKET, BY ISOTOPES 194
7.4.1 DEUTERIUM & O-18 ARE PROMISING ISOTOPES 194
7.4.2 CARBON-13 196
7.4.3 DEUTERIUM 197
7.4.4 OXYGEN-18 198
7.4.5 NITROGEN-15 199
7.4.6 OTHER STABLE ISOTOPES 200
7.5 ENRICHED STABLES MARKET, BY APPLICATIONS 202
7.5.1 DIAGNOSTIC & THERAPEUTIC 203
7.5.2 RESEARCH 204
7.5.3 PHARMACEUTICALS 205
7.5.4 INDUSTRIAL SECTOR 206

8 GEOGRAPHIC ANALYSIS 208

8.1 INTRODUCTION 209
8.2 DIAGNOSTIC MARKET 209
8.2.1 NORTH AMERICA 212
8.2.1.1 Increasing adoption of alternative production technologies to make up for the shortage of Mo-99 213
8.2.2 EUROPE 216
8.2.2.1 Stringent regulations hindering market growth 217
8.2.3 ASIA 220
8.2.3.1 Asia promises the highest CAGR in the forecast period 220
8.2.4 REST OF THE WORLD (ROW) 223
8.3 THERAPY MARKET 227
8.3.1 NORTH AMERICA 230
8.3.1.1 Nuclear medicine research drives the beta emitters market 232
8.3.2 EUROPE 233
8.3.3 ASIA 236
8.3.4 REST OF THE WORLD (ROW) 239
8.4 ENRICHED STABLE ISOTOPES MARKET 242
8.4.1 ASIA 243
8.4.2 NORTH AMERICA 244
8.4.3 EUROPE 246
8.4.4 REST OF THE WORLD (ROW) 248

9 COMPETITIVE LANDSCAPE 251

9.1 INTRODUCTION 251
9.2 MERGERS & ACQUISITIONS 252
9.3 AGREEMENTS, PARTNERSHIPS, COLLABORATIONS &
JOINT VENTURES 253
9.4 PRODUCTS LAUNCH 258
9.5 EXPANSIONS 260
9.6 OTHER DEVELOPMENTS 262
9.7 APPROVALS 266

10 COMPANY PROFILES 268

10.1 COMPANIES 268
10.1.1 BRACCO IMAGING S.P.A. 268
10.1.2 CAMBRIDGE ISOTOPE LABORATORIES, INC. 271
10.1.3 CARDINAL HEALTH, INC. 275
10.1.4 COVIDIEN, PLC 282
10.1.5 ECZACIBASI-MONROL 287
10.1.6 FUJIFILM HOLDINGS CORPORATION 289
10.1.7 GE HEALTHCARE
(SUBSIDIARY OF GENERAL ELECTRIC COMPANY) 294
10.1.8 IBA GROUP 300
10.1.9 ISOTEC, INC. (SIGMA-ALDRICH) 307
10.1.10 LANTHEUS MEDICAL IMAGING, INC. 311
10.1.11 NORDION, INC. 319
10.1.12 NTP RADIOISOTOPES (PTY), LTD. 327
10.1.13 PETNET SOLUTIONS, INC. (A SUBSIDIARY OF SIEMENS MEDICAL SOLUTIONS USA, INC.) 330
10.1.14 TAIYO NIPPON SANSO CORPORATION 336
10.1.15 URENCO LIMITED 340
10.1.16 ROTEM INDUSTRIES, LTD., INC. 344
10.2 INSTITUTES 346
10.2.1 AUSTRALIAN NUCLEAR ASSOCIATION AND TECHNOLOGY ORGANIZATION (ANSTO) 346
10.2.2 BOARD OF RADIATION AND ISOTOPE TECHNOLOGY (BRIT) 350
10.2.3 INSTITUTE OF ATOMIC ENERGY POLATOM RADIOISOTOPE CENTRE 352
10.2.4 INSTITUTE OF ISOTOPES CO., LTD. 355
10.2.5 INSTITUTE OF RADIOELEMENT (IRE) 358

LIST OF TABLES

TABLE 1 RADIOPHARMACEUTICAL DIAGNOSTIC MARKET, BY TECHNOLOGY,
2010 – 2017 ($MILLION) 36
TABLE 2 COST INCREASE OF TC-99M: PHASES OF SUPPLY CHAIN (%) 63
TABLE 3 COST RANGE: NEW & MODIFIED RIG ($MILLION) 64
TABLE 4 COST RANGE: NEW & MODIFIED CONTAINERS ($MILLION) 64
TABLE 5 COST INCREASE FOR LEU-BASED CONVERSION (%) 65
TABLE 6 COST IMPACT: PHASES OF SUPPLY CHAIN ($/6-DAY CURIE) 65
TABLE 7 DETAILS OF RADIOPHARMACEUTICALS FOR UPCOMING DIAGNOSTIC APPLICATIONS, 2010 – 2017 72
TABLE 8 DETAILS OF RADIOPHARMACEUTICALS FOR UPCOMING THERAPEUTIC APPLICATIONS, 2010 – 2017 76
TABLE 9 MO-99: WEEKLY DEMAND (2011) 78
TABLE 10 MO-99: PRODUCTION PER WEEK (2010) 81
TABLE 11 TC-99M: PROCESSING CAPACITY (2011) 83
TABLE 12 MO-99: POTENTIAL REACTORS 84
TABLE 13 GLOBAL RADIOPHARMACEUTICAL DIAGNOSTIC MARKET,
BY TECHNOLOGY, 2010 – 2017 ($MILLION) 98
TABLE 14 GLOBAL SPECT RADIOPHARMACEUTICAL MARKET, BY ISOTOPE,
2010 – 2017 ($MILLION) 101
TABLE 15 SPECT RADIOPHARMACEUTICAL MARKET, BY GEOGRAPHY,
2010 – 2017 ($MILLION) 102
TABLE 16 INDICATIONS DIAGNOSED BY TC-99M 103
TABLE 17 TC-99M MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION) 104
TABLE 18 TL-201 MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION) 107
TABLE 19 GA-67 MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION) 109
TABLE 20 I-123 MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION) 110
TABLE 21 OTHER RADIOPHARMACEUTICALS MARKET, BY GEOGRAPHY,
2010 – 2017 ($MILLION) 112
TABLE 22 PET RADIOPHARMACEUTICALS MARKET, BY GEOGRAPHY,
2010 – 2017 ($MILLION) 114
TABLE 23 GLOBAL PET RADIOPHARMACEUTICALS MARKET, BY ISOTOPE,
2010 – 2017 ($MILLION) 115
TABLE 24 F-18 MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION) 117
TABLE 25 RB-82 MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION) 120
TABLE 26 OTHER PET RADIOPHARMACEUTICALS MARKET, BY GEOGRAPHY,
2010 – 2017 ($MILLION) 121
TABLE 27 GLOBAL BETA EMITTER RADIOPHARMACEUTICALS MARKET,
BY ISOTOPE, 2010 – 2017 ($MILLION) 124
TABLE 28 BETA EMITTER RADIOPHARMACEUTICALS MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION) 125
TABLE 29 I-131 MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION) 127
TABLE 30 Y-90 MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION) 128
TABLE 31 SM-153 MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION) 130
TABLE 32 RE-186 MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION) 131
TABLE 33 LU-177 MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION) 132
TABLE 34 OTHER BETA-EMITTER RADIOPHARMACEUTICALS MARKET,
BY GEOGRAPHY, 2010 – 2017 ($MILLION) 133
TABLE 35 ALPHA EMITTERS VS BETA EMITTERS 134
TABLE 36 HRPCA BONE METASTASIS THERAPY MARKET & ALPHARADIN ADDRESSABLE MARKET, 2015 ($MILLION) 139
TABLE 37 RADIOISOTOPE CHARACTERISTICS & DOSE DELIVERY OVER TIME 142
TABLE 38 GLOBAL BRACHYTHERAPY MARKET, BY ISOTOPE,
2010 – 2017 ($MILLION) 144
TABLE 39 BRACHYTHERAPY MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION) 145
TABLE 40 CS-131 MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION) 146
TABLE 41 I-125 MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION) 147
TABLE 42 PD-103 MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION) 148
TABLE 43 IR-192 MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION) 149
TABLE 44 OTHERS BRACHYTHERAPY MARKET, BY GEOGRAPHY,
2010 – 2017 ($MILLION) 150
TABLE 45 RADIOPHARMACEUTICAL PROCEDURES MARKET, BY GEOGRAPHY,
2010 – 2017 (MILLION) 153
TABLE 46 GLOBAL DIAGNOSTIC RADIOPHARMACEUTICAL PROCEDURES MARKET, BY TECHNOLOGY, 2010 – 2017 (MILLION) 155
TABLE 47 GLOBAL SPECT RADIOPHARMACEUTICAL PROCEDURES MARKET,
BY ISOTOPE, 2010 – 2017 (MILLION) 156
TABLE 48 SPECT RADIOPHARMACEUTICAL PROCEDURES MARKET,
BY GEOGRAPHY, 2010 – 2017 (MILLION) 157
TABLE 49 GLOBAL PET RADIOPHARMACEUTICAL PROCEDURES MARKET,
BY ISOTOPE, 2010 – 2017 (MILLION) 158
TABLE 50 PET RADIOPHARMACEUTICAL PROCEDURES MARKET, BY GEOGRAPHY, 2010 – 2017 (MILLION) 159
TABLE 51 GLOBAL THERAPEUTIC RADIOPHARMACEUTICAL PROCEDURES MARKET, BY TYPE, 2010 – 2017 (MILLION) 160
TABLE 52 GLOBAL BETA EMITTER PROCEDURES MARKET, BY ISOTOPE,
2010 – 2017 (MILLION) 161
TABLE 53 BETA EMITTERS RADIOPHARMACEUTICAL PROCEDURES MARKET,
BY GEOGRAPHY, 2010 – 2017 (MILLION) 162
TABLE 54 GLOBAL BRACHYTHERAPY PROCEDURES MARKET, BY ISOTOPE,
2010 – 2017 (MILLION) 163
TABLE 55 BRACHYTHERAPY RADIOPHARMACEUTICALS MARKET, BY GEOGRAPHY, 2010 – 2017 (MILLION) 164
TABLE 56 SPECT APPLICATION MARKET, 2010 – 2017 ($MILLION) 168
TABLE 57 CARDIOLOGY SPECT MARKET, BY GEOGRAPHY,
2010 – 2017 ($MILLION) 169
TABLE 58 LYMPHOMA SPECT MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION) 170
TABLE 59 THYROID SPECT MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION) 171
TABLE 60 NEUROLOGY SPECT MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION) 173
TABLE 61 OTHER SPECT APPLICATIONS MARKET, BY GEOGRAPHY,
2010 – 2017 ($MILLION) 174
TABLE 62 GLOBAL PET APPLICATION MARKET, 2010 – 2017 ($MILLION) 175
TABLE 63 ONCOLOGY PET MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION) 176
TABLE 64 CARDIOLOGY PET MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION) 177
TABLE 65 NEUROLOGY PET MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION) 179
TABLE 66 OTHER PET APPLICATIONS MARKET, BY GEOGRAPHY,
2010 – 2017 ($MILLION) 180
TABLE 67 GLOBAL RADIOPHARMACEUTICAL MARKET FOR THERAPEUTIC APPLICATIONS,2010 – 2017 ($MILLION) 181
TABLE 68 RADIOPHARMACEUTICAL MARKET FOR THERAPEUTIC APPLICATIONS, BY GEOGRAPHY,2010 – 2017 ($MILLION) 182
TABLE 69 THERAPEUTIC RADIOPHARMACEUTICAL MARKET FOR THYROID APPLICATION, BY GEOGRAPHY,2010 – 2017 ($MILLION) 183
TABLE 70 THERAPEUTIC RADIOPHARMACEUTICAL MARKET FOR BONE METASTASIS APPLICATION, BY GEOGRAPHY, 2010 – 2017 ($MILLION) 184
TABLE 71 THERAPEUTIC RADIOPHARMACEUTICAL MARKET FOR LYMPHOMA APPLICATION, BY GEOGRAPHY, 2010 – 2017 ($MILLION) 186
TABLE 72 THERAPEUTIC RADIOPHARMACEUTICAL MARKET FOR ENDOCRINE APPLICATION, BY GEOGRAPHY, 2010 – 2017 ($MILLION) 187
TABLE 73 THERAPEUTIC RADIOPHARMACEUTICAL MARKET FOR OTHER APPLICATIONS, BY GEOGRAPHY, 2010 – 2017 ($MILLION) 188
TABLE 74 GLOBAL STABLE ISOTOPE MARKET, 2010 – 2017 ($MILLION) 194
TABLE 75 STABLE ISOTOPE MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION) 195
TABLE 76 CARBON STABLE ISOTOPE MARKET, BY GEOGRAPHY,
2010 – 2017 ($MILLION) 197
TABLE 77 DEUTERIUM STABLE ISOTOPE MARKET, BY GEOGRAPHY,
2010 – 2017 ($MILLION) 198
TABLE 78 OXYGEN STABLE ISOTOPE MARKET, BY GEOGRAPHY,
2010 – 2017 ($MILLION) 199
TABLE 79 NITROGEN STABLE ISOTOPE MARKET, BY GEOGRAPHY,
2010 – 2017 ($MILLION) 200
TABLE 80 OTHER STABLE ISOTOPE MARKET, BY GEOGRAPHY,
2010 – 2017 ($MILLION) 201
TABLE 81 GLOBAL ENRICHED STABLE ISOTOPE MARKET, BY APPLICATION,
2010 – 2017 ($MILLION) 202
TABLE 82 STABLE ISOTOPES MARKET FOR MEDICAL APPLICATIONS,
BY GEOGRAPHY, 2010 – 2017 ($MILLION) 203
TABLE 83 STABLE ISOTOPES MARKET FOR RESEARCH APPLICATIONS,
BY GEOGRAPHY, 2010 – 2017 ($MILLION) 205
TABLE 84 STABLE ISOTOPES MARKET FOR PHARMACEUTICAL APPLICATIONS,
BY GEOGRAPHY, 2010 – 2017 ($MILLION) 206
TABLE 85 STABLE ISOTOPES MARKET FOR INDUSTRIAL APPLICATIONS,
BY GEOGRAPHY, 2010 – 2017 ($MILLION) 207
TABLE 86 DIAGNOSTIC RADIOPHARMACEUTICALS MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION) 210
TABLE 87 SPECT RADIOPHARMACEUTICALS MARKET, BY GEOGRAPHY,
2010 – 2017 ($MILLION) 211
TABLE 88 PET RADIOPHARMACEUTICALS MARKET, BY GEOGRAPHY,
2010 – 2017 ($MILLION) 212
TABLE 89 NORTH AMERICA: RADIOPHARMACEUTICAL DIAGNOSTIC MARKET,
BY TECHNOLOGY, 2010 – 2017 ($MILLION) 214
TABLE 90 NORTH AMERICA: SPECT RADIOPHARMACEUTICAL MARKET,
BY ISOTOPE, 2010 – 2017 ($MILLION) 215
TABLE 91 NORTH AMERICA: PET RADIOPHARMACEUTICAL MARKET, BY ISOTOPE, 2010 – 2017 ($MILLION) 216
TABLE 92 EUROPE: RADIOPHARMACEUTICAL DIAGNOSTIC MARKET,
BY TECHNOLOGY, 2010 – 2017 ($MILLION) 218
TABLE 93 EUROPE: SPECT RADIOPHARMACEUTICAL MARKET, BY ISOTOPE,
2010 – 2017 ($MILLION) 219
TABLE 94 EUROPE: PET RADIOPHARMACEUTICAL MARKET, BY ISOTOPE,
2010 – 2017 ($MILLION) 220
TABLE 95 ASIA: RADIOPHARMACEUTICAL DIAGNOSTIC MARKET,
BY TECHNOLOGY, 2010 – 2017 ($MILLION) 221
TABLE 96 ASIA: SPECT RADIOPHARMACEUTICAL MARKET, BY ISOTOPE,
2010 – 2017 ($MILLION) 222
TABLE 97 ASIA: PET RADIOPHARMACEUTICAL MARKET, BY ISOTOPE,
2010 – 2017 ($MILLION) 223
TABLE 98 ROW: RADIOPHARMACEUTICAL DIAGNOSTIC MARKET,
BY TECHNOLOGY, 2010 – 2017 ($MILLION) 224
TABLE 99 ROW: SPECT RADIOPHARMACEUTICAL MARKET, BY ISOTOPE,
2010 – 2017 ($MILLION) 225
TABLE 100 ROW: PET RADIOPHARMACEUTICAL MARKET, BY ISOTOPE,
2010 – 2017 ($MILLION) 226
TABLE 101 BETA EMITTER MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION) 228
TABLE 102 BRACHYTHERAPY MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION) 229
TABLE 103 NORTH AMERICA: RADIOPHARMACEUTICAL MARKET, BY THERAPY, 2010 – 2017 ($MILLION) 230
TABLE 104 NORTH AMERICA: BRACHYTHERAPY MARKET, BY ISOTOPE,
2010 – 2017 ($MILLION) 231
TABLE 105 NORTH AMERICA: BETA EMITTER MARKET, BY ISOTOPE,
2010 – 2017 ($MILLION) 232
TABLE 106 EUROPE: RADIOPHARMACEUTICAL MARKET, BY THERAPY,
2010 – 2017 ($MILLION) 233
TABLE 107 EUROPE: BRACHYTHERAPY MARKET, BY ISOTOPE,
2010 – 2017 ($MILLION) 234
TABLE 108 EUROPE: BETA EMITTER MARKET, BY ISOTOPE,
2010 – 2017 ($MILLION) 235
TABLE 109 ASIA: RADIOPHARMACEUTICAL MARKET, BY THERAPY,
2010 – 2017 ($MILLION) 236
TABLE 110 ASIA: BRACHYTHERAPY MARKET, BY ISOTOPE,
2010 – 2017 ($MILLION) 237
TABLE 111 ASIA: BETA EMITTER MARKET, BY ISOTOPE, 2010 – 2017 ($MILLION) 238
TABLE 112 ROW: RADIOPHARMACEUTICAL MARKET, BY THERAPY,
2010 – 2017 ($MILLION) 239
TABLE 113 ROW: BRACHYTHERAPY MARKET, BY ISOTOPE,
2010 – 2017 ($MILLION) 240
TABLE 114 ROW: BETA EMITTER MARKET, BY ISOTOPE, 2010 – 2017 ($MILLION) 241
TABLE 115 ENRICHED STABLE ISOTOPE MARKET, BY GEOGRAPHY,
2010 – 2017 ($MILLION) 242
TABLE 116 ASIA: STABLE ISOTOPE MARKET, 2010 – 2017 ($MILLION) 243
TABLE 117 ASIA: ENRICHED STABLE ISOTOPE MARKET, BY APPLICATION,
2010 – 2017 ($MILLION) 244
TABLE 118 NORTH AMERICA: ENRICHED STABLE ISOTOPE MARKET,
2010 – 2017 ($MILLION) 245
TABLE 119 NORTH AMERICA: STABLE ISOTOPE MARKET, BY APPLICATION,
2010 – 2017 ($MILLION) 246
TABLE 120 EUROPE: ENRICHED STABLE ISOTOPE MARKET,
2010 – 2017 ($MILLION) 247
TABLE 121 EUROPE: ENRICHED STABLE ISOTOPE MARKET, BY APPLICATION,
2010 – 2017 ($MILLION) 248
TABLE 122 ROW: ENRICHED STABLE ISOTOPE MARKET, 2010 – 2017 ($MILLION) 249
TABLE 123 ROW: ENRICHED STABLE ISOTOPE MARKET, BY APPLICATION,
2010 – 2017 ($MILLION) 250
TABLE 124 MERGERS & ACQUISITIONS, 2010 – 2012 252
TABLE 125 AGREEMENTS, PARTNERSHIPS, COLLABORATIONS & JOINT VENTURES, 2010 – 2013 253
TABLE 126 PRODUCTS LAUNCH, 2010 –2013 258
TABLE 127 EXPANSIONS, 2010 –2012 260
TABLE 128 OTHER DEVELOPMENTS, 2010 – 2012 262
TABLE 129 APPROVALS, 2010 – 2011 266
TABLE 130 CAMBRIDGE ISOTOPE LABORATORIES INC.: TOTAL REVENUE,
BY SEGMENT, 2010 – 2012 ($MILLION) 272
TABLE 131 CAMBRIDGE ISOTOPE LABORATORIES INC.: TOTAL REVENUE,
BY GEOGRAPHY, 2010 – 2012 ($MILLION) 273
TABLE 132 CARDINAL HEALTH, INC.: TOTAL REVENUE, BY SEGMENT,
2010 – 2012 ($MILLION) 276
TABLE 133 CARDINAL HEALTH, INC.: TOTAL REVENUE, BY GEOGRAPHY,
2010 – 2012 ($MILLION) 277
TABLE 134 COVIDIEN, PLC: TOTAL REVENUE AND R&D EXPENDITURE,
2010 – 2012 ($MILLION) 283
TABLE 135 COVIDIEN, PLC: TOTAL REVENUE, BY SEGMENT,
2010 – 2012 ($MILLION) 283
TABLE 136 COVIDIEN, PLC: TOTAL REVENUE, BY GEOGRAPHY,
2010 – 2012 ($MILLION) 285
TABLE 137 FUJIFILM HOLDINGS CORP: TOTAL REVENUE, BY SEGMENT,
2010 – 2012 ($MILLION) 291
TABLE 138 FUJIFILM HOLDINGS CORP: TOTAL REVENUE, BY GEOGRAPHY,
2010 – 2012 ($MILLION) 291
TABLE 139 GENERAL ELECTRIC COMPANY: TOTAL REVENUE AND R&D EXPENSES, 2009 – 2011 ($BILLION) 295
TABLE 140 GENERAL ELECTRIC COMPANY: TOTAL REVENUE, BY SEGMENT,
2009 – 2011 ($BILLION) 295
TABLE 141 GENERAL ELECTRIC COMPANY: TOTAL REVENUE, BY GEOGRAPHY,
2009 – 2011 ($BILLION) 296
TABLE 142 IBA GROUP: MARKET REVENUE, BY SEGMENT, 2009 – 2011 ($MILLION) 302
TABLE 143 IBA GROUP: TOTAL REVENUE, BY GEOGRAPHY,
2009 – 2011 ($MILLION) 303
TABLE 144 ISOTEC INC.: TOTAL REVENUE, BY SEGMENT, 2009- 2011 ($MILLION) 308
TABLE 145 ISOTEC INC.: TOTAL REVENUE, BY GEOGRAPHY,
2009 – 2011 ($MILLION) 309
TABLE 146 LANTHEUS: TOTAL REVENUE, BY SEGMENT, 2009 – 2011 ($MILLION) 313
TABLE 147 LANTHEUS: TOTAL REVENUE, BY GEOGRAPHY,
2009 – 2011 ($MILLION) 314
TABLE 148 NORDION, INC.: TOTAL REVENUE, BY SEGMENT,
2010 – 2012 ($MILLION) 321
TABLE 149 NORDION, INC.: TOTAL REVENUE, BY GEOGRAPHY,
2009 – 2011 ($MILLION) 321
TABLE 150 SIEMENS AG: TOTAL REVENUE AND R&D EXPENSES,
2010 – 2012 ($MILLION) 331
TABLE 151 SIEMENS AG: TOTAL REVENUE, BY SEGMENT, 2010 – 2012 ($MILLION) 331
TABLE 152 SIEMENS AG: TOTAL REVENUE, BY GEOGRAPHY,
2010 – 2012 ($MILLION) 332
TABLE 153 TAIYO NIPPON SANSO, CORP.: TOTAL REVENUE, BY GEOGRAPHY,
2010 – 2012 ($MILLION) 338

LIST OF FIGURES

FIGURE 1 GLOBAL RADIOPHARMACEUTICAL MARKET, BY SEGMENT, 2010 – 2017 36
FIGURE 2 RADIOPHARMACEUTICALS MARKET, BY GEOGRAPHY, 2012 ($MILLION) 37
FIGURE 3 GLOBAL STABLE ISOTOPES MARKET, 2012 – 2017 ($MILLION) 39
FIGURE 4 EVOLUTION OF RADIOPHARMACEUTICALS 41
FIGURE 5 RADIOPHARMACEUTICALS MARKET SEGMENTATION 43
FIGURE 6 ENRICHED STABLE ISOTOPES MARKET SEGMENTATION 44
FIGURE 7 MARKET DYNAMICS 45
FIGURE 8 RADIOPHARMACEUTICALS: MARKET SHARE ANALYSIS,
BY KEY PLAYERS, 2012 56
FIGURE 9 ENRICHED STABLE ISOTOPE: MARKET SHARE ANALYSIS,
BY KEY PLAYERS, 2012 59
FIGURE 10 MO-99/TC-99M: SUPPLY CHAIN 60
FIGURE 11 TC-99M: SUPPLY CHAIN PARTICIPANTS 61
FIGURE 12 TC-99M: VALUE CHAIN ANALYSIS 61
FIGURE 13 TC-99M: PRICING FACTORS 66
FIGURE 14 FLUORINE-18: SUPPLY CHAIN 67
FIGURE 15 DEUTERIUM: SUPPLY CHAIN 68
FIGURE 16 MAJOR SPONSORS, CLINICAL STUDIES, 2010 – 2017 69
FIGURE 17 CLINICAL TRIALS FOR DIAGNOSTIC & THERAPEUTIC APPLICATIONS OF RADIOISOTOPES, BY PHASE, 2010 – 2017 70
FIGURE 18 CLINICAL TRIALS (PHASE III & IV) FOR DIAGNOSTIC RADIOISOTOPES, 2010 – 2017 71
FIGURE 19 UPCOMING RADIOPHARMACEUTICAL APPLICATIONS (DIAGNOSIS), 2010 – 2017 71
FIGURE 20 CLINICAL TRIALS (PHASE III & IV) FOR THERAPEUTIC RADIOISOTOPES, 2010 – 2017 74
FIGURE 21 UPCOMING RADIOPHARMACEUTICAL APPLICATIONS (THERAPY),
2010 – 2017 75
FIGURE 22 MO-99 DEMAND (SIX DAYS CURIE) PER WEEK, 2012 VS 2030 78
FIGURE 23 MO-99: SUPPLY VS DEMAND ANALYSIS, 2010 – 2020 85
FIGURE 24 SHIFT TOWARDS LEU FROM HEU 86
FIGURE 25 SUSTAINABLE SUPPLY CHAIN & LOGISTICS 89
FIGURE 26 OPPORTUNITY MATRIX: GLOBAL DIAGNOSTIC RADIOPHARMACEUTICALS MARKET (2012) 99
FIGURE 27 SPECT RADIOISOTOPE MARKET SHARE (2012) 100
FIGURE 28 PET RADIOPHARMACEUTICALS MARKET SHARE (2012) 113
FIGURE 29 OPPORTUNITY MATRIX: GLOBAL THERAPEUTIC RADIOPHARMACEUTICALS MARKET (2012) 123
FIGURE 30 RA-223 DECAY CHAIN 135
FIGURE 31 PORTER'S FIVE FORCES ANALYSIS FOR ALPHARADIN 138
FIGURE 32 SWOT ANALYSIS OF ALPHARADIN 140
FIGURE 33 GLOBAL RADIOPHARMACEUTICAL PROCEDURES MARKET, 2012 154
FIGURE 34 DIAGNOSTIC RADIOPHARMACEUTICALS MARKET, BY INDICATION (2012) 167
FIGURE 35 KEY GROWTH STRATEGIES, 2010 – 2013 251
FIGURE 36 CAMBRIDGE ISOTOPE LABORATORIES INC.: TOTAL REVENUE AND R&D EXPENSES, 2010 – 2012 ($BILLION) 272
FIGURE 37 CARDINAL HEALTH, INC.: TOTAL REVENUE, 2010 – 2012 ($BILLION) 276
FIGURE 38 COVIDIEN, PLC: RADIOPHARMACEUTICALS REVENUE,
2010 – 2012 ($BILLION) 284
FIGURE 39 FUJIFILM HOLDINGS CORP: TOTAL REVENUE AND R&D EXPENDITURE, 2010 – 2012 ($BILLION) 290
FIGURE 40 IBA GROUP: TOTAL MARKET REVENUE, 2009 – 2011 ($MILLION) 301
FIGURE 41 ISOTEC INC.: TOTAL REVENUE AND R&D EXPENSES,
2009 – 2011 ($BILLION) 308
FIGURE 42 LANTHEUS: TOTAL REVENUE AND R&D EXPENSES,
2009 – 2011 ($MILLION) 312
FIGURE 43 NORDION, INC.: TOTAL MARKET REVENUE, 2010 – 2012 ($BILLION) 320
FIGURE 44 TAIYO NIPPON SANSO, CORP.: TOTAL REVENUE AND R&D EXPENDITURE, 2010 – 2012 ($BILLION) 337
FIGURE 45 URENCO LIMITED: TOTAL MARKET REVENUE, 2009 – 2011 ($BILLION) 341

To order this report:
Medical_Imaging Industry: Nuclear Medicine/Radiopharmaceuticals [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha radiation therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & Stable Isotopes (Deuterium, C-13) Market - Global Trends & Forecast to 2017

Contact Clare: clare@reportlinker.com  
US:(339) 368 6001
Intl:+1 339 368 6001

SOURCE Reportlinker